2[3]Walletin J, Ohlsson E. Fragmin during instability in coro nary artery disease (FRISC) study group. Low molecular weight heparin during instability in coronary atery disease.Lancet, 1996; 347: 561
4[5]Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or asprin in the treatment of usntable angina and silent ischemia. J Am Coll Cardiol, 1995;26:313
5[6]Ferguson JM. Meeting highlight-the 1995 euriopean society of cardioloy. Circulation, 1995;92:2359
6[7]Aron Glick, Ran Komowski, Yoaw Michowich, et al. Re duction of reinfarction and angina with use of LMWH therapy after Streptokinase (and heparin) in acute myocardial infarction.AM J Cardiol, 1996;77:1145
7[8]Nesvold A, Kontny F, Abildgaard U, et al. Safety of high doses of low molecular weight heparin (Fragmin) in acute my ocardial infarction. Thromb Res, 1991 ;64(5) :579
8[9]Dempfle CE, Kontoy F, Abildgaard U, et al. Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Thromb Haemost, 1999;81(5) :701
9[10]Frederic k, Jon D, Ulrich A, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of lefe ventricular thrombus formation and arterial embolisrn after acute anterior myocardial infarction the fragmin in acute myocardial Infarction (FRAMI) study. JACC, 1997;30(4):962
10[11]Ferguson JJ. The 1995 European society of cardiology.Circulation, 1995; 92 (9): 2395
